North Chicago, Illinois Tuesday, March 4, 2025, 10:00 Hrs [IST] ...

Abbvie Inc. is buying into the obesity fray in a potential $1.875 billion development and commercialization agreement with ...

AbbVie inked a licensing deal Monday worth up to $2.23 billion for an amylin-targeting obesity treatment from Denmark-based ...

More tepid economic news and a pledge by Donald Trump to push through tariffs on top trading partners stressed Wall Street ...

Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, ...

AbbVie partners with Gubra in a $2.2 billion deal to develop GUB014295, an amylin analog for obesity. The move marks AbbVie's entry into the competitive weight-loss market.

The stagflation specter is spooking traders today, wiping out the risk-on move that was buoying stocks and weighing on board ...

Police are holding two more suspects over the murder of a Scottish businessman in Kenya. Campbell Scott's body was found tied up in a sack of pineapples in a forest 60 miles (96.5km) from Nairobi, ...

In a partnership marking AbbVie’s entrance into the weight management field, the US pharma major has signed a licensing deal ...

AbbVie (ABBV) on Monday said it struck a licensing deal with Danish biotechnology company Gubra to develop a potential candidate for obesity treatment. AbbVie will be responsible for the global ...

A rebound in stocks sputtered as data showed US manufacturing approached stagnation amid a jump in prices. The S&P 500 erased gains, with a slide in megacaps like Nvidia Corp. and Microsoft Corp. also ...

NORTH CHICAGO, IL, USA and HØRSHOLM, Denmark I March 3, 2025 I AbbVie (NYSE: ABBV) and Gubra A/S (CPSE:GUBRA), a company specializing in preclinical ...